Navigation Links
Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
Date:8/19/2010

5,776,964 5,328,052 Other receivables 2,354,237 995,657 Other receivables - related parties 33,035,274 44,561,626 Employee advances 238,075 115,673 Prepaid expenses 351,905 658,193 Prepaid taxes 121,542 407,534 Total current assets 56,348,506 69,294,375 PROPERTY, PLANT AND EQUIPMENT, net 9,946,030 10,124,483 OTHER ASSETS: Construction in progress 146,343,059 125,572,621 Construction deposits 5,068,290 1,405,997 Intangible assets, net 12,764,848 12,864,295 Other assets 18,039,203 11,847,937 Total other assets 182,215,400 151,690,850 Total assets $248,509,936 $231,109,708 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $4,387,829 $5,012,157 Advances from customers - related parties 17,055,922 4,426,751 Wages and benefits payable 788,451 1,484,852 Income taxes payable 330,095 -- Contractor deposits 258,403 183,395 Contractor payables 20,942,557 18,513,216 Other payables 1,248,953 1,151,551 Other payables - related parties 1,502,767 3,326,110 Total current liabilities 46,514,977 34,098,032 NON-CURRENT LIABILITIES Deferred income 11,283,364 11,236,501 Total non current liabilities 11,283,364 11,236,501 Total liabilities 57,798,341 45,334,533 EQUITY: Shareholders' equity of the Company: Common stock, $0.001 par value, 250,000,000 shares authorized, 71,333,586 issued and outstanding, respectively 71,334 71,334 Paid-in-capital 18,194,133 18,042,189 Statutory reserves 16,465,144 13,217,217 Retained earnings 126,769,661 126,370,263 Accumulated other comprehensive income 18,880,529 18,262,123 Total shareholders' equity of the Company 180,380,801 175,963,126 Noncontrolling interest 10,330,794 9,812,049 Total equity 190,711,595 185,775,175 Total liabilities and equity $248,509,936 $231,109,708 TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, 2010 AND 2009 (UNAUDITED) Six months ended June 30, 2010 2009 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $4,111,465 $19,315,168 Adjustme
'/>"/>
SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
4. Tiens Biotech Group (USA) Reports First Quarter Results
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Yongye Biotechnology International Retains CCG Investor Relations
7. ThirdBiotech Announces Kemeta as Newest Sponsor
8. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
9. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
10. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Kangtai Cactus Biotech Announces Record Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine”) (TSX: IMV), ... announced that the U.S. Food and Drug Administration ... and Phase I clinical trials of the DPX-Anthrax ... co-development agreement signed with Gilead Life Sciences. The ... the DPX-Survivac. , “We have been in talks ...
(Date:2/27/2015)... 27, 2015 FamilyFarms Group is pleased ... of State Line Farms, received the 2015 Tomorrow’s Top ... under the age of 35, who has demonstrated excellence ... honor to win the Tomorrow's Top Producer Horizon Award. ... the Top Producer Award and learning from their experiences. ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
(Date:2/26/2015)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today reported 2014 full ... key objectives, and financial guidance.  Synageva,s management team ... p.m. EST to review the financial results and ... today,s call by telephone, please dial (877) 445-4603 ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... 2007 Net Income of $13.1 Million, DUBLIN, Calif., ... pharmaceutical company dedicated to the discovery, rapid,development and commercialization ... financial results for the fourth,quarter and year ended December ... the 2007 fourth quarter of $5.1,million, or $0.09 per ...
... Osteotech, Inc.,(Nasdaq: OSTE ), a leader in ... announced today that Sam Owusu-Akyaw, Osteotech,s,President and Chief ... Orthopedics Conference at the Mission Bay Conference Center ... to present at 3:10 p.m.,Pacific Time on Tuesday, ...
... /PRNewswire-FirstCall/-- Dendreon Corporation (Nasdaq:,DNDN) announced the publication ... marker of antigen presenting cell activation" in ... supports the use of CD54 as a ... activation and validates,its utility as a potency ...
Cached Biology Technology:SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 2SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 3SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 4SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 5SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 6SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 7SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 8SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 9SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 10SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 11SuperGen Reports 2007 Fourth Quarter and Annual Financial Results 12Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation 2Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation 3
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Diseases from a mutation in one genome are ... between two genomes: the DNA in the nucleus and ... how such genomic disconnects cause disease. In a step ... University have traced one such incompatibility in fruit flies ...
... and the Federation of European Biochemical Societies (FEBS) announce Genevive ... as the winner of the 2013 FEBS | EMBO Women ... for her outstanding contributions to research in the area of ... and her active role in mentoring female scientists. The FEBS ...
... between two individuals in a population is crucial in ... New research has laid the foundation for a new ... for more targeted prevention strategies. By using novel ... Review Letters , outlines a predictive model of a ...
Cached Biology News:Mitochondrial mutations: When the cell's 2 genomes collide 2Mitochondrial mutations: When the cell's 2 genomes collide 3Geneviève Almouzni to receive the 2013 FEBS | EMBO Women in Science Award 2Geneviève Almouzni to receive the 2013 FEBS | EMBO Women in Science Award 3Can you predict how a disease will spread in a population? 2
Mouse monoclonal antibody to PAEP - progestagen-associated endometrial protein (placental protein 14, pregnancy-associated endometrial alpha-2-globulin, alpha uterine protein)...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
... Rabbit polyclonal to BMP2 ... factor beta (TGFB) superfamily. Bone morphogenic ... a candidate gene for the autosomal ... progressiva. Immunogen: Synthetic ...
Biology Products: